Figure 5.

ATX interacts with glycoprotein IIb/IIIa. (A) Binding assay demonstrating an interaction between ATX and platelets that is inhibited by the addition of RGDS peptide (n = 4). (B) Binding of autotaxin to platelets is negated by GR144053 (n = 4). (C) Treatment with glycoprotein IIb/IIIa inhibitor (GR144053) abrogates platelet-induced valve interstitial cell mineralization (n = 6). (D) Platelet-associated ATX activity in control and calcific aortic valve stenosis patients (n = 27). (E and F) Spearman correlations between platelet-associated autotaxin activity and peak transaortic velocity (E) and aortic valve area (F) (n = 27). RGDS: 0.1–1µM (DMSO: 0.02µL/mL), GR144053: 60 nM (H₂O). Values are mean ± standard deviation. ATX, autotaxin; AVA, aortic valve area; CAVS, calcific aortic valve stenosis; CTL, control; DMSO, dimethyl sulfoxyde; RFU, relative fluorescence unit; RGDS, arginyl-glycyl-α-aspartyl-serinyl.